Literature DB >> 21203627

A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.

Nicholas T Salzameda1, Lisa M Eubanks, Joseph S Zakhari, Kyoji Tsuchikama, Nicholas J DeNunzio, Karen N Allen, Mark S Hixon, Kim D Janda.   

Abstract

Clostridium botulinum produces the most lethal toxins known to man, as such they are high risk terrorist threats, and alarmingly there is no approved therapeutic. We report the first cross-over small molecule inhibitor of these neurotoxins and propose a mechanism by which it may impart its inhibitory activity.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21203627      PMCID： PMC3065946          DOI： 10.1039/c0cc04078a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  26 in total

1.  High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity.

Authors:  C Anne; F Cornille; C Lenoir; B P Roques
Journal:  Anal Biochem       Date:  2001-04-15       Impact factor: 3.365

2.  Partial protection against Botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity.

Authors:  Christine Anne; Serge Turcaud; Armand G S Blommaert; François Darchen; Eric A Johnson; Bernard P Roques
Journal:  Chembiochem       Date:  2005-08       Impact factor: 3.164

3.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

Authors:  Grant E Boldt; Jack P Kennedy; Kim D Janda
Journal:  Org Lett       Date:  2006-04-13       Impact factor: 6.005

4.  A detergent-based assay for the detection of promiscuous inhibitors.

Authors:  Brian Y Feng; Brian K Shoichet
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 5.  Bacterial toxins: a table of lethal amounts.

Authors:  D M Gill
Journal:  Microbiol Rev       Date:  1982-03

6.  Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.

Authors:  Ryan A Reinke; Peter J King; Joseph G Victoria; Brenda R McDougall; Guoxiang Ma; Yingqun Mao; Manfred G Reinecke; W Edward Robinson
Journal:  J Med Chem       Date:  2002-08-15       Impact factor: 7.446

7.  Development of potent inhibitors of botulinum neurotoxin type B.

Authors:  Christine Anne; Serge Turcaud; Jean Quancard; Franck Teffo; Hervé Meudal; Marie-Claude Fournié-Zaluski; Bernard P Roques
Journal:  J Med Chem       Date:  2003-10-23       Impact factor: 7.446

8.  L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro.

Authors:  Ryan A Reinke; Deborah J Lee; Brenda R McDougall; Peter J King; Joseph Victoria; Yingqun Mao; Xiangyang Lei; Manfred G Reinecke; W Edward Robinson
Journal:  Virology       Date:  2004-09-01       Impact factor: 3.616

9.  Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity.

Authors:  M Adler; J D Nicholson; F Cornille; B E Hackley
Journal:  FEBS Lett       Date:  1998-06-16       Impact factor: 4.124

10.  SNARE motif and neurotoxins.

Authors:  O Rossetto; G Schiavo; C Montecucco; B Poulain; F Deloye; L Lozzi; C C Shone
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.